Literature DB >> 10416536

Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?

S Aizawa, H Gatanaga, S Ida, A Sakai, M Tanaka, Y Takahashi, Y Hirabayashi, S Oka.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10416536     DOI： 10.1097/00002030-199907090-00021

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  2 in total

1.  Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).

Authors:  A Hachiya; S Aizawa-Matsuoka; M Tanaka; Y Takahashi; S Ida; H Gatanaga; Y Hirabayashi; A Kojima; M Tatsumi; S Oka
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.

Authors:  Saori Matsuoka-Aizawa; Hironori Sato; Atsuko Hachiya; Kiyoto Tsuchiya; Yutaka Takebe; Hiroyuki Gatanaga; Satoshi Kimura; Shinichi Oka
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.